微孔板法与GeneXpert MTB/RIF技术检测结核分枝杆菌对利福平耐药性的价值

doi:10.3969/j.issn.1000-6621.2019.02.008

摘要/Abstract

摘要：

目的探讨微孔板法和GeneXpert MTB/RIF(简称“GeneXpert”)技术检测MTB对利福平(RFP)耐药性的价值。方法收集陕西省结核病防治院2017年收住入院和门诊诊治的疑似结核病患者6893例,按照临床诊断标准确诊为结核病患者6086例,同时使用BACTEC MGIT 960液体培养(简称“MGIT 960法”)和GeneXpert技术检测上述确诊患者的425份临床标本;其中,痰标本217份、肺泡灌洗液标本170份、肺外标本(包括胸腹腔积液、脓液,脑脊液等)38份;排除3例报告错误或无法判读、2例培养结果污染的标本,有效标本份数为420份。对其中GeneXpert技术和MGIT 960液体培养均为阳性的372株临床分离株同时进行微孔板法、GeneXpert技术和MGIT 960耐药性检测,其中痰标本191例、肺泡灌洗液标本158例、肺外标本(包括胸腹腔积液、脓液及脑脊液等)23例,以MGIT 960检测结果为标准,分析微孔板法和GeneXpert技术检测结核分枝杆菌对RFP耐药性的诊断价值。结果 GeneXpert技术、微孔板法和MGIT 960法对RFP耐药性检测总的阳性率分别为18.8%(70/372)、16.7%(62/372)、16.7%(62/372)。以MGIT 960法检测结果为标准,微孔板法和GeneXpert法对利福平耐药性检测的敏感度、特异度、符合率、Kappa值分别为91.9%(57/62)、98.4%(305/310)、97.3%(362/372)、0.8,96.8%(60/62)、96.8%(300/310)、96.8%(360/372)、0.8;微孔板法和GeneXpert法对痰液、肺泡灌洗液、肺外标本利福平耐药性检测的敏感度、特异度、符合率、Kappa值分别为96.7%(29/30)、98.1%(158/161)、97.9%(187/191)、0.9,93.3%(28/30)、96.3%(155/161)、95.8%(183/191)、0.9, 91.7%(22/24)、98.5%(132/134)、97.5%(154/158)、0.9和100.0%(24/24)、97.0%(130/134)、97.5%(154/158)、0.9,75.0%(6/8)、100.0%(15/15)、91.3%(21/23)、0.8,100.0%(8/8)、100.0%(15/15)、100.0%(23/23)、1.0。结论以MGIT 960检测结果为标准,微孔板法和GeneXpert技术对利福平耐药性检测总的阳性率和不同标本对利福平耐药性检测的阳性率均具有较好的一致性。

关键词: 分枝杆菌,结核, 利福平, 结核,抗多种药物性, 核酸扩增技术, 微生物敏感性试验, 对比研究

Abstract:

Objective To compare the results of Mycobacterium tuberculosis (MTB) resistance to rifampicin (RFP) by Micropore-plate method (Microdrug sensitivity, MicroDST) and GeneXpert MTB/RIF test. Methods Among the 6893 suspected MTB patients who admitted to or visited Outpatient Department in Shaanxi Provincial Tuberculosis Control and Prevention Hospital, 6086 patients were diagnosed as MTB cases according to the clinical diagnostic criteria. A total of 425 clinical specimens were tested by BACTEC MGIT 960 liquid culture method and GeneXpert method, including 217 sputum specimens, 170 alveolar lavage specimens, and 38 extrapulmonary fluid specimens (such as pleural and peritoneal effusion, pus and cerebrospinal fluid). After excluding 3 specimens that reported errors or could not be interpreted and 2 specimens that were contaminated when cultured, there were 420 valid specimens. Three hundred and seventy-two clinical isolates with positive results by GeneXpert and MGIT 960 method were tested for drug resistance by MicroDST, GeneXpert MTB/RIF and MGIT 960 method, including 191 sputum specimens, 158 alveolar lavage specimens, and 23 extrapulmonary fluid specimens (such as pleural and peritoneal effusion, pus and cerebrospinal fluid). Taking MGIT 960 test as the gold standard, the performance of MicroDST and GeneXpert MTB/RIF in detecting MTB resistance to RFP were compared. Results The overall positive rates of RFP resistance by GeneXpert MTB/RIF, MicroDST and MGIT 960 method were 18.8% (70/372), 16.7% (62/372), and 16.7% (62/372), respectively. Taking MGIT 960 test as the gold standard, the sensitivity, specificity, coincidence rate and Kappa value of RFP resistance test were 91.9% (57/62), 98.4% (305/310), 97.3% (362/372) and 0.8 by MicroDST assay and 96.8% (60/62), 96.8% (300/310), 96.8% (360/372) and 0.8 by GeneXpert MTB/RIF assay. The sensitivity, specificity, coincidence rate and Kappa value using sputum, alveolar lavage and extrapulmonary specimens were 96.7% (29/30), 98.1% (158/161), 97.9% (187/191), 0.9; 93.3% (28/30), 96.3% (155/161), 95.8% (183/191), 0.9; and 91.7% (22/24), 98.5% (132/134), 97.5% (154/158), 0.9 by MicroDST assay and 100.0% (24/24), 97.0% (130/134), 97.5% (154/158), 0.9; 75.0% (6/8), 100.0% (15/15), 91.3% (21/23), 0.8; and 100.0% (8/8), 100.0% (15/15), 100.0% (23/23), 1.0 by GeneXpert MTB/RIF assay, respectively. Conclusion Taking MGIT 960 test as the gold standard, MicroDST and GeneXpert MTB/RIF assay have a good consistency in overall positive detection rate of RFP resistance, as well as in different samples.

Key words: Mycobacterium tuberculosis, Rifampin, Tuberculosis,multidrug-resistant, Nucleic acid amplification techniques, Microbial sensitivity tests, Comparative study

李静,梁亚萍,王卓,陈基平,王智存,仵倩红. 微孔板法与GeneXpert MTB/RIF技术检测结核分枝杆菌对利福平耐药性的价值[J]. 中国防痨杂志, 2019, 41(2): 162-168. doi: 10.3969/j.issn.1000-6621.2019.02.008

Jing LI,Ya-ping LIANG,Zhuo WANG,Ji-ping CHEN,Zhi-cun WANG,Qian-hong WU. The value of MicroDST and GeneXpert MTB/RIF test in detecting Mycobacterium tuberculosis resistance to rifampicin[J]. Chinese Journal of Antituberculosis, 2019, 41(2): 162-168. doi: 10.3969/j.issn.1000-6621.2019.02.008

图/表 6

表1

表2

表3

表4

表5

表6

参考文献 27

[1]	World Health Organization . Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
[2]	Wor1d Health Organization . Global tuberculosis report 2016. Geneva:World Heahh Organization, 2016.
[3]	王胜芬, 赵冰, 宋媛媛 , 等. 我国耐药结核病的危险因素——2007年全国结核病耐药基线调查资料分析. 中国防痨杂志, 2013,35(4):221-226.
[4]	唐神结 . 耐药结核病综合治疗的回顾与展望. 结核病与肺部健康杂志, 2014,3(3):141-147.
[5]	肖和平 . 抗结核药物的合理使用是控制耐药结核病流行的基石. 中华结核和呼吸杂志, 2014,37(10):723-724.
[6]	陈伟, 夏愔愔, 李涛 , 等. 2015年全球及中国结核病疫情形势分析. 结核病与肺部健康杂志, 2016,5(1):32-36.
[7]	银春莲 . 结核病耐药的研究现状及对策. 内科, 2011,6(1):73-75.
[8]	曾熙玲, 初乃惠, 刘志敏 . 耐药结核病辅助治疗的进展. 结核病与肺部健康杂志, 2013,2(4):222-227.
[9]	Boehme CC, Nabeta P, Hillemann D , et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med, 2010,363(11):1005-1015. doi: 10.1056/NEJMoa0907847 URL
[10]	张治国, 欧喜超, 孙倩 , 等. 利福平耐药实时荧光定量核酸扩增技术检测痰标本中结核核分枝杆菌及其耐药性的研究. 中国防痨杂志, 2013,35(1):13-16.
[11]	李敏, 崔庆, 张晶磊 . 18例肺结核误诊原因分析. 重庆医学, 2009,38(11):1390-1391.
[12]	Steingart KR, Schiller I, Home DJ , et al.Xpert MTB/RIF assay forpulmonary tuberculosisand rifampicin resistance in adults.Cochrane Data base Syst Rev, 2014, 21(1):CD009593.
[13]	Pimkina E, Zablockis R, Nikolayevskyy V , et al. The Xpent MTB/RIF assay in routine diagnosis of pulmonary tuberculosis:amulticentre study in Lithuania. Respir Med, 2015,109(11):1484-1489. doi: 10.1016/j.rmed.2015.07.006 URL
[14]	Kim YW, Kwak N, Seong MW , et al. Accuracy of the Xpert MTB/RIF assay for the diagnosis of extra-pulmonary tuberculosis in South Korea. Int J Tuberc Lung Dis, 2015,19(1):81-86. doi: 10.5588/ijtld.14.0500 URL
[15]	杨建, 王西娣, 陈美玲 , 等. 2013—2015年陕西省地区分枝杆菌对利福平耐药性及rpoB基因突变相关研究. 现代检验医学杂志, 2016,31(2):53-55.
[16]	张天华, 刘卫平, 李岩 , 等. 陕西省肺结核耐药性监测分析. 中国热带医学, 2017,17(3):226-230.
[17]	刘婷, 温贵华, 陈伊 , 等. Xpert MTB/RIF在结核病诊断及利福平耐药中的应用. 国际检验医学杂志, 2016,37(10):1368-1370.
[18]	Calligaro GL, Theron G, Khalfey H , et al. Burden of tuberculosis in intensive care units in Cape Town,South Africa,and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on trachecl aspirate samples for diagnosis of pulmonary tuberculosis:a prospective burden of disease study with a nested randomised controlled trial. Lancet Respir Med, 2015,3(8):621-630. doi: 10.1016/S2213-2600(15)00198-8 URL
[19]	崔振玲, 王洁, 黄晓辰 , 等. 微量液体培养法快速鉴别分枝杆菌. 中华预防医学杂志, 2011,45(1):17-20.
[20]	王洁, 陆俊梅, 黄晓辰 , 等. 微量MIC检测判断结核分枝杆菌药敏的方法学研究. 中华检验医学杂志, 2010,33(4):315-319.
[21]	布红丽, 杨顺利, 智霞萍 , 等. 分枝杆菌微量药敏测定与罗氏绝对浓度法药敏测定的比较研究. 山西医药杂志, 2011,40(9):855-856.
[22]	吴晓渊, 刘正华, 施旭东 , 等. 结核分枝杆菌快速微量直视培养药敏试验方法的研究. 临床检验杂志, 2007,25(6):430-431.
[23]	World Health Organization . Rapid impiementatiao of the Xpert MTB/RIF diagnostic test: technical and operational ‘How to’; practical considerations. Geneva:World Health Organization, 2011.
[24]	李妍, 张天华, 鲜小萍 , 等. Xpert MTB/RIF技术在 MTB检测中的应用价值. 检验医学, 2016,31(1):52-55. doi: 10.3969/j.issn.1673-8640.2016.01.012
[25]	郑杨, 夏辉, 赵雁林 . TREK Sensititre ^®MYCOTB检测结核分枝杆菌对一、二线抗结核药物的敏感性研究 . 中国防痨杂志, 2015,37(6):597-602.
[26]	谭守勇, 谭耀驹, 黎燕琼 , 等. 对利福平耐药的结核分枝杆菌rpoB基因突变与耐药程度关系的探讨. 中国实用内科杂志, 2004,24(1):27-29.
[27]	Hall L, Jude KP, Clark SL , et al. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and second-line agents. J Clin Microbio1, 2012,50(11):3732-3734. doi: 10.1128/JCM.02048-12 URL

检测技术	痰液(191份)		肺泡灌洗液(158份)		肺外标本(23份)		合计(372份)
检测技术	耐药份数	检出率(%)	耐药份数	检出率(%)	耐药份数	检出率(%)	耐药份数	检出率(%)
微孔板法	32	16.8	24	15.2	6	26.1	62	16.7
GeneXpert技术	34	17.8	28	17.7	8	34.8	70	18.8
MGIT 960法	30	15.7	24	15.2	8	34.8	62	16.7